Companies: PwC · McKesson · Option Care Health · Clayton, Dubilier & Rice

Distributors Are Moving Into Specialty Care. The $5.8B McKesson Deal Shows Why RCM Is the Next Battleground.

A drug distributor is no longer necessarily just the company delivering the medication. In specialty care, the emerging opportunity is to connect the drug, the practice, the site of care, and the transaction that pays for treatment. McKesson's newly announced Option Care deal shows what that shift can look like—and why revenue cycle intelligence becomes strategically important.

Healthcare distributors have historically competed on scale, logistics, access to manufacturers, and procurement economics. Specialty medicine introduces a different set of problems: expensive therapies, complex coverage rules, prior authorization, drug acquisition risk, payer-specific reimbursement, and patients moving among offices, infusion centers, and home settings.

PwC's distributor-led specialty provider integration topic raises an important question for investors and revenue cycle leaders: what happens when the company supplying specialty drugs also becomes more involved in how, where, and by whom those drugs are administered?

McKesson offers a timely, concrete case.

The Deal: Distribution Meets the Site of Care

On October 6, Reuters reported that McKesson and private equity firm Clayton, Dubilier & Rice agreed to acquire Option Care Health in a roughly $5.8 billion transaction, including debt.

Option Care serves more than 308,000 patients annually through over 197 locations, delivering home and ambulatory infusion therapies and specialty pharmacy services. McKesson is expected to invest approximately $1.4 billion for an initial 49% ownership stake, retaining a right to purchase the rest in the future. Option Care is expected to operate separately under its management team, and closing is anticipated in the first half of 2027.

That distinction matters: this is an announced acquisition structure, not an already completed transfer of every physician or infusion operation into a single entity.

But the strategic direction is difficult to miss. McKesson already operates specialty distribution and practice-support businesses. Option Care would deepen its exposure to the locations and services where specialty medicines are actually delivered.

The Buy-and-Bill Model Is Where the Economics Converge

Many specialty practices operate under buy-and-bill economics: they acquire a medication, administer it to a patient, and pursue reimbursement for both the drug and the associated clinical service. Not every specialty drug or care setting uses this model, but where it does apply, the provider carries important timing and payment risk.

An expensive infused therapy can be clinically appropriate and still create a financial loss if coverage verification fails, prior authorization is incomplete, the wrong billing unit is reported, acquisition costs exceed reimbursement, or payment takes too long.

The distributor understands sourcing and acquisition costs. The provider understands the treatment. The payer controls coverage and reimbursement. RCM teams have to reconcile all three.

Bring those workflows closer together, and the platform potentially gains a more complete picture of margin per therapy, payer, provider, and site of care. That information can inform purchasing, contracting, scheduling, drug inventory, billing, collections, and patient access.

This is where reimbursement intelligence stops being a back-office report and becomes operating infrastructure.

Specialty RCM Is More Than Claim Submission

The attractive part of integration is not simply centralizing the billing team. It is the possibility of addressing the entire specialty therapy financial pathway:

• Before treatment: benefit investigation, referral verification, medical versus pharmacy benefit determination, authorization, site-of-care requirements, and patient financial counseling.
• At the point of care: drug selection, inventory tracking, NDC-to-HCPCS mapping, units and wastage documentation, administration coding, and charge capture.
• After treatment: claim reconciliation, denial prevention, underpayment recovery, payer-policy monitoring, and timely cash conversion.

Those functions cross the traditional boundaries among supply chain, clinical operations, contracting, and RCM. When they are disconnected, problems propagate from one department to another.

For distributors investing in specialty care, closing the loop could be more economically important than acquiring another standalone software tool.

McKesson Already Has a Provider Operating Footprint

This is not McKesson's first step beyond wholesale distribution.

The US Oncology Network, supported by McKesson, describes a nationwide network with more than 3,300 affiliated providers and hundreds of sites of care. Its physician relationships include practice management, reimbursement analytics, managed-care contracting, revenue cycle support, billing and coding, and value-based care services.

McKesson also markets specialty practice solutions covering drug purchasing, technology, practice management, and infusion operations. These relationships vary by affiliation and contract structure; participation in the network does not mean every affiliated practice is owned by McKesson.

That existing footprint shows why distribution can become a route into operational influence. The same organization may be positioned to support drug supply, care operations, data, and the financial workflows linking the two.

The competitive threat to independent specialty RCM vendors is not only that distributors could build better billing tools. It is that they could bundle financial execution with purchasing relationships and practice infrastructure.

The Site-of-Care Shift Creates a Second Revenue Cycle

Infusion therapies increasingly span physician offices, hospital outpatient departments, ambulatory infusion suites, and patients' homes. Each setting carries different reimbursement mechanics, payer constraints, staffing needs, and drug handling requirements.

A platform that can help direct appropriate treatments to appropriate settings may support patient access and cost efficiency. But the financial analysis must account for what the provider actually gets paid—not simply the cheapest physical location.

For RCM organizations, the core questions include: Who bills for the drug? Who bills for administration? Which benefit applies? What authorization and provider-network rules govern the setting? Who owns denials and appeals when a patient moves between sites?

The more distributed specialty care becomes, the more valuable coordinated eligibility, authorization, contracted-rate, and payment data could become.

The Acquisition Thesis Has Real Friction

Vertical integration is not automatically better for patients or providers. Larger platforms can bring scale and working capital, but they may also create conflicts between drug purchasing economics, site-of-care decisions, referral patterns, and clinical judgment.

Ownership and affiliation arrangements also operate within corporate-practice-of-medicine rules, federal and state fraud-and-abuse restrictions, privacy obligations, payer contracts, and competition law. Independent physician governance and clinical decision-making require careful protection.

Revenue cycle integration adds its own risks: inconsistent charge masters, payer-specific billing logic, disparate EHR systems, pharmacy benefit carve-outs, and errors when drug supply data do not match clinical documentation.

Those are material operational constraints—not details that disappear merely because distribution and care delivery share an investor.

What RCM Investors and Operators Should Watch

There are three practical indicators that distributor-led specialty platforms are becoming more integrated:

• Payer and acquisition-cost intelligence: investment in real net reimbursement and drug economics at the NDC, HCPCS, payer, and site-of-care level.
• Closed-loop revenue operations: shared visibility from referral and authorization through administration, submission, adjudication, and collections.
• Outcome-based service models: contracts that reward completed treatments, denial reduction, better cash conversion, and measurable financial performance rather than transaction volume alone.

These measures are an RCAI framework for evaluating the opportunity, not reported results of the pending Option Care transaction.

RCAI Take

The next specialty-care consolidator may not look like a traditional physician practice management company.

It may begin as a drug distributor with supply-chain scale, manufacturer relationships, purchasing data, and access to thousands of specialty providers. It can then add practice operations, infusion capacity, patient navigation, payer intelligence, and financial services.

McKesson's announced Option Care transaction is a tangible example of that strategic direction. PwC's broader focus on distributor-led specialty integration points to the same question: who will control the economic infrastructure surrounding specialty treatment?

For independent RCM vendors, the challenge is to prove capabilities these larger ecosystems cannot easily absorb: differentiated payer intelligence, specialty-specific payment accuracy, interoperable automation, and demonstrable improvement in cash realization.

Distribution gets the drug to the practice. The next competitive battleground is who gets the treatment authorized, administered, billed, and paid.

Sources and methodology: PwC, Distributor-Led Specialty Provider Integration (topic reference; full page text was unavailable for independent review at publication); Reuters, October 6, 2026 McKesson–Option Care transaction report; The US Oncology Network; and PwC's provider partnership analysis. Transaction facts and network descriptions are sourced as linked. RCM implications, potential benefits, and risks are independent RevCycleAI analysis.